JPMorgan Raises Target's Price Target to $120 Following Strong Q4 Performance
Money

JPMorgan Raises Target's Price Target to $120 Following Strong Q4 Performance

authorBy Chika Uwazie
DateMar 15, 2026
Read time2 min

JPMorgan has raised its price target for Target Corporation (TGT) to $120 from $115, while keeping a Neutral rating on the stock, following the release of Target's robust fourth-quarter earnings. This upward revision reflects an optimistic outlook based on the retailer's recent financial performance. The firm's updated internal models factored in the positive outcomes from Target's latest quarterly report.

Moreover, Target unveiled a comprehensive multi-year growth strategy on March 3, spearheaded by CEO Michael Fiddelke. This strategic blueprint emphasizes strengthening key merchandise categories, increasing investments in employee payroll and training, and revitalizing the in-store shopping environment. The plan outlines four core areas of focus: delivering innovative and culturally relevant product assortments, enriching the consumer journey through digital platforms and physical store enhancements, leveraging advanced technology to create seamless and personalized shopping experiences, and fostering strong teams while supporting local communities.

The company intends to allocate over $1 billion to operational improvements in 2026, alongside an additional $5 billion in capital expenditures for supply chain optimizations, technological advancements, store renovations, and the establishment of new locations. These initiatives include plans for more than 130 full-store remodels and over 30 new store openings. Furthermore, Target will expand its product offerings in high-demand segments such as home goods, beauty, baby products, groceries, wellness items, women's fashion, and fan-centric merchandise. The retailer also aims to enhance its loyalty programs, same-day fulfillment, and next-day delivery services across 20 new metropolitan areas, ensuring a consistent, engaging, and convenient shopping experience for its diverse customer base.

Target Corporation's strategic investments in its operations, technology, and customer experience underscore its commitment to sustained growth and market leadership. By focusing on innovation, personalization, and community engagement, Target is positioning itself for continued success in the dynamic retail landscape, offering an inspiring example of a company evolving to meet consumer needs while fostering a positive impact.

More Articles
Coffee Titans Face Off: Dutch Bros vs. Starbucks
The coffee market is a competitive battleground, with daily coffee consumption high in the U.S. This article analyzes Dutch Bros and Starbucks, two major players with distinct strategies. Dutch Bros, a rapidly expanding drive-thru chain, shows strong growth in revenue and new store openings, appealing to growth investors. Starbucks, a global giant, is implementing a revitalization plan to restore its market position, making it an attractive option for value investors. The choice between these two depends on individual investment goals.
By JL CollinsMar 15, 2026
Barclays Lowers Marsh & McLennan Price Target, Citing Undervalued Brokerage Model
Barclays has reduced its price target for Marsh & McLennan Companies, Inc. (MRSH) to $209, down from $210, while maintaining an Overweight rating. This adjustment comes despite a recent selloff in the insurance brokerage sector driven by AI disruption concerns, which the firm believes are overblown. Barclays emphasizes MRSH's strong market position and its ability to capitalize on efficiency gains from AI, suggesting the company's valuation currently underestimates the resilience of its brokerage model and AI's potential to boost profitability.
By Chika UwazieMar 15, 2026
KBW Adjusts Price Target for Hippo Holdings Inc. to $33 Amidst Growth Concerns
KBW has lowered its price target for Hippo Holdings Inc. (HIPO) from $34 to $33, while maintaining a Market Perform rating. This adjustment reflects concerns regarding the company's ambitious growth projections for 2028, which are juxtaposed with a challenging market environment characterized by weakening pricing trends in the insurance sector. Despite a positive financial performance in Q4 2025, with net profits and significant premium growth, analysts foresee potential hurdles for sustained expansion.
By Mr. Money MustacheMar 15, 2026
Amgen Halts Anti-OX40 Clinical Trials Due to Emerging Safety Concerns
Amgen Inc. and Kyowa Kirin have ceased all ongoing clinical studies for rocatinlimab, an anti-OX40 monoclonal antibody. This decision follows a safety review revealing new malignancy cases, including Kaposi's sarcoma, despite the overall incidence remaining within expected background levels. The companies prioritize patient safety, concluding that potential risks outweigh therapeutic benefits for those enrolled in trials for asthma, prurigo nodularis, and atopic dermatitis. Further analysis of the complete safety data is underway, and regulatory bodies have been notified.
By Ramit SethiMar 15, 2026
American Express Bolsters Cardmember Benefits and Shareholder Returns
American Express (AXP) has announced significant expansions in card member benefits across New York/New Jersey and Atlanta, forging partnerships with major sports venues and teams. Concurrently, the company's Board of Directors authorized a 16% increase in the quarterly dividend for common shareholders, demonstrating a commitment to enhancing both customer value and investor returns. These strategic moves highlight AXP's dual focus on market engagement and financial growth.
By Scott PapeMar 15, 2026